Proteomic mapping of dynamic changes in kinase signaling after drug treatment identifies that AURKA inhibition is required for drug sensitivity, representing a new co-targeting opportunity with PI3K, AKT, or mTOR inhibitors in breast cancer.
- Hayley J. Donnella
- James T. Webber
- Sourav Bandyopadhyay
